Skip to main content
Fosun Pharma - Shanghai Fosun Pharmaceutical(Group)Co., Ltd.

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Adhering to the mission of improving human health, Fosun Pharma’s business covers all key sectors of healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices and medical diagnosis, as well as pharmaceutical distribution and retail, with pharmaceutical manufacturing and R&D as the core, and healthcare services as the development focus.

Fosun Pharma regards innovation, research and development as the core driving factor of development and has developed international R&D team in China, the United States., India and etc., and established innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform. Currently, Fosun Pharma continues to focus on therapeutic areas including oncology, cardiovascular system, central nervous system, blood system, metabolism and alimentary system and anti-infection. All major products occupy the leading position and maintained fast growth in each market segment.  

In healthcare service segment, Fosun Pharma Group has strategically layout high-end medical in developed coastal cities, specialized and general hospital in second and third-tier cities. In 2018, the combined number of authorized beds controlled by Fosun Pharma including Chancheng Hospital, Hengsheng Hospital, Zhongwu Hospital, Wenzhou Geriatrics Hospital, Guangji Hospital, Jimin Cancer Hospital, Zhuhai Chancheng and Wuhan Jihe Hospital, etc. was 4,118 in aggregate. United family hospital, the affiliated hospital of Fosun Pharma Group, continues to maintain its leading position in premium healthcare in Beijing, Tianjin, Shanghai and other metropolitan in China.

Looking forward, Fosun Pharma will adhere to the brand philosophy of “Innovation for Good Health”. Focusing on the unmet medical needs, it will stick to the development model of “organic growth, external expansion and integrated development” under the guidance of “4IN” strategy (Innovation, Internationalization, Integration, Intelligentization), striving to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market.

Organization type